Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Center for Instrument Sharing of the University of Pisa (CISUP) Lungarno Pacinotti 43 56126 Pisa Italy.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Center for Instrument Sharing of the University of Pisa (CISUP) Lungarno Pacinotti 43 56126 Pisa Italy.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Center for Instrument Sharing of the University of Pisa (CISUP) Lungarno Pacinotti 43 56126 Pisa Italy.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Center for Instrument Sharing of the University of Pisa (CISUP) Lungarno Pacinotti 43 56126 Pisa Italy.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Center for Instrument Sharing of the University of Pisa (CISUP) Lungarno Pacinotti 43 56126 Pisa Italy.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Center for Instrument Sharing of the University of Pisa (CISUP) Lungarno Pacinotti 43 56126 Pisa Italy.
Department of Animal Sciences, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot 761001, Israel.
School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
First-line treatment for Cushing´s disease is transsphenoidal surgery. But in cases of persistent or recurrent disease after surgery, contraindications to surgery, severe hypercortisolism control befo...
Peripartum cardiomyopathy (PPCM) is a left ventricular systolic dysfunction associated with heart failure (HF) in late-term pregnancy or peripartum. A 29-year-old pregnant woman with no history of car...
Prolactinomas are one of the most common pituitary neuroendocrine tumors (PitNETs), accounting for approximately 50% of all pituitary tumors. Dopamine agonists are the main treatment for prolactinoma,...
The expression of circOMA1 in prolactinoma tissues was examined by quantitative reverse transcription PCR (qRT-PCR). The biological function of circOMA1 was evaluated in vitro and in vivo. To explore ...
circOMA1 was overexpressed in drug-resistant prolactinoma tissues compared with sensitive prolactinoma samples. We further found that circOMA1 promoted MMQ cells growth in vivo and in vitro. In additi...
The present study demonstrates that circOMA1 attenuates CAB efficacy through ferroptosis resistance and may be a new therapeutic target for the individualized treatment of DA-resistant prolactinoma pa...
The aim of this study was to evaluate the efficacy of cabergoline in normalizing plasma IGF-I levels in acromegaly patients with elevated IGF-I levels after surgery and/or SRL therapy. Acromegaly pati...
The aim of this study was to estimate the budget impact of adding cabergoline to the Brazilian Unified Health System (SUS) formulary for the treatment of patients with Cushing's disease (CD) who do no...
We conducted a budget impact analysis (BIA) from the perspective of the Brazilian SUS over a 5-year time horizon. We compared two scenarios: ketoconazole (Scenario 1) versus including cabergoline as a...
The total costs were BRL $25,596,729 for Scenario 1 and BRL $32,469,169 for Scenario 2. The budget impact of adding cabergoline to the formulary for CD treatment within the SUS would be BRL $6,091,036...
The estimated budget impact of adding cabergoline to the formulary for CD treatment within the Brazilian SUS would be about BRL $6 million. While cost savings cannot be expected, the budget impact of ...
A macro pituitary tumour or giant pituitary tumour is regarded as a rare causal factor in syndrome of inappropriate antidiuretic hormone (SIADH) cases. Previous reports have presented findings showing...
Both prolactin excess and autoimmune (Hashimoto) thyroiditis may predispose to the development of cardiometabolic disorders. The aim of this study was to investigate whether autoimmune thyroiditis det...
In recent years, dopamine agonists (DAs) have become an attractive therapeutic option to prevent both tumor growth and post-surgical tumor remnant growth in clinically non-functioning pituitary adenom...
To analyze our experience on the effect of cabergoline (CAB) on tumor remnant after initial surgery in NFPA patients....
A retrospective and multicenter study of NFPA patients with tumor remnant after surgery treated with CAB was performed....
From a total of 142 NFPA patients (79 men, 55.2%; mean age 57.2 ± 14.2 year) who underwent surgery, we selected 62/142 (43.7%) patients (32 men, 51.6%; mean age 59.3 ± 13.9 year) with tumor persistenc...
Although the present study showed no significant differences in the type of tumor response between the CAB and OBS groups of patients, the percentage of PR was higher and that of progression lower in ...
A 60-year-old patient, professor of physics, presented in 1999 with sudden-onset vitiligo associated with hyperprolactinemia and a prolactinoma. Fearful of potential surgical complications at the peak...
Hypoprolactinemia, which is usually a consequence of treatment with inadequate high doses of dopaminergic agents, is a poorly understood clinical condition. The aim of the current study was to investi...
We studied two groups of cabergoline-treated premenopausal women with hypercholesterolemia matched for age, plasma lipids, cabergoline dose, and treatment duration: 11 women with hypoprolactinemia (gr...
Patients with hypoprolactinemia were more insulin-resistant, had lower values of total testosterone and free androgen index, and had higher levels of hsCRP and fibrinogen than individuals with normal ...
Coexisting hypoprolactinemia may have an unfavorable impact on the pleiotropic effects of statins....